DNM1 and acute lymphoblastic leukemia: The in vivo efficacy noted with dynole 34-2 suggests that on-going development in this family of compounds may generate a true drug lead, but while tolerated and synergistic with current chemotherapy regimes in mouse models of T-ALL and MAL, the current lack of known binding site within dynamin limits the potential for a rational drug design approach.